Certolizumab - CISMeF

Preferred Label : Certolizumab;

NCIt definition : A Fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha), with anti-inflammatory activity. Upon administration, certolizumab binds to TNF-alpha, preventing the interaction of this cytokine with endogenous cell surface receptors, thereby rendering TNF-alpha inactive and inhibiting TNF-mediated inflammatory responses. TNF-alpha is a protein involved in inflammation, cell survival, and apoptosis.;

UNII : G6ADW90R16;

NCI Metathesaurus CUI : CL430555;

Details

Origin ID

C97947;

UMLS CUI

C1872109;

Automatic exact mappings (from CISMeF team)
- CDP870 [MeSH concept]
- Certolizumab pegol [Substance BNPC]
Currated CISMeF NLP mapping
- CERTOLIZUMAB [SMS substance]
- Certolizumab [LOINC component]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Certolizumab [LOINC component]
- Certolizumab Pegol [MeSH Descriptor]
- Certolizumab pegol (substance) [SNOMED CT concept]
- Product containing certolizumab pegol (medicinal product) [SNOMED CT concept]
- certolizumab pegol [ATC Code]
- certolizumab pegol [MeSH concept]
Validated automatic mappings to BTNT
- certolizumab pegol [MeSH concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients